Core Viewpoint - The company has received FDA approval for its drug IMM2510/AXN-2510 to initiate Phase I clinical trials in the U.S., leading to a milestone payment of $10 million from Instil, reflecting ongoing progress and commitment in their partnership [1] Group 1 - The total payments received under the licensing and collaboration agreement with Instil have reached $30 million, including milestone payments [1] - IMM2510/AXN-2510 is a bispecific antibody targeting PD-L1 and VEGF, currently being developed for the treatment of various solid tumors [1] - The drug differentiates itself from other PD-(L)1xVEGF bispecific antibodies by blocking multiple VEGF receptor ligands beyond VEGF-A, utilizing PD-L1 as an anchor point in the tumor microenvironment, and enhancing antibody-dependent cellular cytotoxicity (ADCC) to directly kill PD-L1 positive tumor cells [1]
宜明昂科-B(01541.HK)已从Instil收取1000万美元的里程碑付款